Case Page

 

Case Status:    DISMISSED    
On or around 10/16/2018 (Notice of voluntarily dismissal)

Filing Date: March 27, 2018

According to the Complaint, Solid Biosciences, Inc. purportedly seeks to cure Duchenne muscular dystrophy, or DMD. The Company’s lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients’ muscles. The Company’s therapy uses adeno-associated virus (AAV) to deliver the transgene into the patient.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, Defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects, were materially false and/or misleading.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: SLDB
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Massachusetts
DOCKET #: 18-CV-10587
JUDGE: Hon. Mark L. Wolf
DATE FILED: 03/27/2018
CLASS PERIOD START: 01/25/2018
CLASS PERIOD END: 03/14/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Andrews DeValerio LLP
    265 Franklin Street, Suite 1702, Andrews DeValerio LLP, MA 02110
    617.936.2796 ·
  2. Glancy Prongay & Murray LLP
    1925 Century Park East, Suite 2100 , Glancy Prongay & Murray LLP, CA 90067
    (310) 201-9150 (310) 432-1495 ·
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available